Receptor in Biological Technology

SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS

... property portfolio of proprietary taste receptor technologies. As of June 30, 2009, Senomyx is ... activity in the Company's proprietary sweet receptor screening assays. Recent efforts include the ... the protein Senomyx believes is the primary receptor responsible for human salt taste perception. ...

AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction

... supporting the use of AEterna Zentaris' ghrelin receptor antagonist compound, AEZS-123 (JMV2959), for the ... the administration of AEZS-123, and a ghrelin receptor mouse knockout model, highlights the role of ... actions are blocked by administering ghrelin receptor antagonists such as AEZS-123, mice no longer show ...

AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting

... in male patients." Results LHRH receptor expression was demonstrated in more than 95% of ... majority of specimens showed moderate to strong receptor expression. Statistically, strong receptor expression correlated with higher pathologic ...

ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week

... chemokine receptor. Targeting the CCR9 chemokine receptor represents a novel approach for the treatment of ... Efficacy of the Intestine-Specific Chemokine receptor Antagonist CCX282-B (Traficet-EN) in Treatment of ... receptor. In adults, CCR9 is a highly specific receptor expressed by T cells that migrate selectively to ...

SENOMYX ANNOUNCES FIRST QUARTER 2009 FINANCIAL RESULTS

... property portfolio of proprietary taste receptor technologies. As of March 31, 2009, Senomyx is ... Senomyx is using the Company's proprietary sweet receptor screening technology to identify enhancers of ... the protein Senomyx believes is the primary receptor responsible for human salt taste perception, the ...

Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB

... AXL1717,an insulin-like growth factor-1 (IGF-1) receptor inhibitor which has no effects on the closely ... cancer patients in the future." The IGF-1 receptor is a promising target for the treatment of cancer, since the receptor is crucial for the survival and growth of ...

Neurocrine Biosciences Reports First Quarter 2009 Results

... Corticotropin Releasing Factor (CRF1) receptor Antagonists for Anxiety/Depression and IBS ... affinity and selective antagonists for the CRF1 receptor that are currently in clinical development for ... GSK has advanced a novel lead CRF1 receptor antagonist compound, 561679, into a Phase II ...

ChemoCentryx Identifies Novel Small Molecule C5aR Antagonist

... medicinally relevant inhibitor compounds, C5a receptor has been a target of epic difficulty in the ... CCX168 is a highly potent and specific C5a receptor small molecule antagonist, and unlike other ... lymphocytes to the site of inflammation. The C5a receptor is highly expressed on innate immune cells, ...

Preclinical Data From Amgen's Oncology Pipeline to be Presented at AACR

... of the type 1 insulin-like growth factor receptor (IGF-1R) and AMG 102, a fully human monoclonal ... 1:00 pm - 5:00 pm) -- Dual targeting of the receptor tyrosine kinase EGFRvIII and HGF:c-Met ... 2009, 3:40 pm - 3:55 pm) -- Erythropoietin receptor (EpoR) Was Expressed at Low to Undetectable ...

Palonosetron Warrants Adequate Caloric Intake in Oncology Patients Receiving High Emetogenic Chemotherapy

... that palonosetron, a second generation 5-HT3 receptor antagonist, warrants adequate caloric intake in ... types of emetogenic chemotherapy. The 5-HT3 receptor plays a pivotal role in the process of emesis, and agents that antagonise these receptor subtypes are the basis for control of this ....

Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia

... of ITI-007 that can act simultaneously as a 5HT2A receptor antagonist, dopamine receptor phosphoprotein modulator (DPPM), and inhibitor of ... mechanisms beyond simple 5HT2A receptor antagonism. As such, ITI-007 represents a novel ...

Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients

... clinical trial of the Company's novel androgen receptor antagonist MDV3100 in castration-resistant ... prognosis. Overexpression of the androgen receptor is believed to contribute to the progression of ... MDV3100 is a novel small-molecule androgen receptor antagonist that inhibits ...

Valdoxan(R) Granted Marketing Authorisation for the Treatment of Major Depressive Episodes in Europe

... profile is a result of its unique receptor profile. Valdoxan is the first antidepressant with melatonin receptor (MT1) and (MT2) agonist properties and 5-hydroxytryptamine (serotonin) receptor 2C (5-HT2C) antagonist properties. This ...

SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS

... property portfolio of proprietary taste receptor technologies. As of December 31, 2008, Senomyx ... the protein the Company believes is the primary receptor responsible for human salt taste. Using new ... is a leading company using proprietary taste receptor technologies to discover and develop novel flavor ...

Global Biopharmaceutical Leader in Peptide Research Expands Commitment in San Diego/U.S. With New R&D Facility and Ready-To-Market Prostate Cancer Treatment Degarelix

... include: barusiban (FE 200440), an oxytocin receptor antagonist; FE 202158, a selective V1a receptor agonist; FE 200665 (a.k.a. CR665), a first generation peripherally-selective kappa opioid receptor agonist; FE 202845 (a.k.a. CR845), a second ...

First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated

... of NGX426, an AMPA/kainate-type glutamate receptor antagonist, was safe and well-tolerated in ... product candidates: two ionotropic glutamate receptor antagonists and one muscarinic receptor agonist. Further information is available at ...

SENOMYX ANNOUNCES INITIATION OF DEVELOPMENT ACTIVITIES FOR NEW BITTER BLOCKERS

... property portfolio of proprietary taste receptor technologies, including patents related to bitter ... and nucleic acid sequences that encode many T2R receptor subunits, as well as variants of these bitter ... is a leading company using proprietary taste receptor technologies to discover and develop novel flavor ...

Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights

... studies using its proprietary Toll-like receptor 3 agonist, Poly IC-Poly Arginine ... vaccine adjuvant targeting the Toll-like receptor 3 (TLR3) pathway. Data showed that ... the human papillomavirus (HPV); and a Toll- like receptor 3 (TLR3) agonist for use as a vaccine adjuvant ...

SENOMYX ANNOUNCES THIRD QUARTER 2008 FINANCIAL RESULTS

... of sodium chloride that are active in our salt receptor assays is an important step toward our goal ... property portfolio of proprietary taste receptor technologies. As of September 30, 2008, Senomyx ... sample extracts that were active in the sweet receptor screening assay. These samples, which typically ...

Neurocrine Biosciences Reports Third Quarter 2008 Results

... nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix. The primary endpoint, ... Health. Corticotropin Releasing Factor (CRF1) receptor Antagonists for Anxiety/Depression and IBS The ... in 2008. GSK has advanced a novel lead CRF1 receptor antagonist compound, 561679, into a Phase II ...

MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology

... granulocyte-macrophage colony stimulating factor receptor (GM-CSFR). CAM-3001 is a phase 1 clinical ... -- ICOS - ICOS (Inducible costimulator) is a receptor on activated T-cells that plays a central ... vitro properties of CAM-3001, a human anti GM-CSF receptor antibody for the treatment of patients with ...

FDA Approves Astellas' Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia

... Arginine vasopressin (AVP) receptor antagonist now approved in single-use ... Astellas, Vaprisol, an arginine vasopressin (AVP) receptor antagonist, is the first and only approved drug ... with hyponatremia. Vaprisol is the first AVP receptor antagonist with a demonstrated safety profile and ...

Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients

... demonstrating that the Company's novel androgen receptor antagonist MDV3100 continues to show promising ... poor prognosis. Overexpression of the androgen receptor is believed to contribute to the progression of ... MDV3100 is a novel small- molecule androgen receptor antagonist that inhibits androgen receptor ...

TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel

... effects. By acting at both the AMPA and kainate receptor site to competitively block the binding of ... product candidates: two ionotropic glutamate receptor antagonists and one muscarinic receptor agonist. Further information is available at ...

ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 Into Clinical Development

... Leadership Position in Targeting Chemokine receptor CCR9 for Gastrointestinal ... compound that inhibits the chemokine receptor known as CCR9. Structurally distinct from ... oral, highly-specific inhibitors of the chemokine receptor known as 'CCR9', which is predominantly expressed ...

Lilly to Acquire ImClone Systems in $6.5 Billion Transaction

... that targets the insulin- like growth factor-1 receptor (IGF-1R). Phase II testing is underway in breast, ... antibody that targets the epidermal growth factor receptor (EGFR), the same receptor targeted by ERBITUX. It is currently in Phase II ...

TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel

... is the first AMPA/kainate-type glutamate receptor antagonist to be studied in clinical trials for ... effects. By acting at both the AMPA and kainate receptor site to competitively block the binding of ... four product candidates: two ionotropic glutamate receptor antagonists and ...

Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908

... 63908, a partial agonist of the nicotinic alpha-7 receptor being developed in collaboration with ... the second compound in our nicotinic alpha-7 receptor program, has the potential to address serious ... filed with Health Canada. Nicotinic Alpha-7 receptor Agonist Collaboration with Roche R4996/MEM ...

Getting Ready Corporation and Winston Laboratories, Inc. Announce Completion of Merger

... compound is civamide, a TRPV-1 (transient receptor potential vanilloid-1) receptor modulator, which we believe provides ... is a patented, synthetically produced TRPV-1 receptor modulator, which selectively depresses the ...

TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds

... in October 2007, tezampanel, an AMPA/kainate receptor antagonist, met its primary endpoint of headache ... product candidates: two ionotropic glutamate receptor antagonists and one muscarinic receptor agonist. Further information is available at ...

US Neuropathic Pain Market Value Doubles to $5 Billion by 2018

... capsaicin (NeurogesX) and a dual cannabinoid receptor agonist (GW/Bayer), and fentanyl buccal ... III development in the US including two GABA receptor agonists pregabalin (Pfizer) and gabapentin GR ... (GSK/Novo Nordisk); an alpha-2 adrenergic receptor antagonist/norepinehrine reuptake inhibitor ...

ReceptorBio Announces Diabetes License Agreement With Telik

... to continue the development of the insulin receptor activator compounds discovered by Telik," said ... that acts by targeting and activating the insulin receptor should provide a novel treatment for this ... compound, RB101, believed to activate the insulin receptor tyrosine kinase (IRTK), a recognized drug target ...

Neurocrine Biosciences Reports Second Quarter 2008 Results

... Health. Corticotropin Releasing Factor (CRF1) receptor Antagonists for Anxiety/Depression and IBS The ... GSK will soon be advancing a novel lead CRF1 receptor antagonist compound, 561679, into a Phase II ... for further clinical studies; risk that the CRF1 receptor antagonist candidate's Phase II proof of concept ...

Addrenex Pharmaceuticals Licenses New Compound to Sciele Pharma for the Treatment of Hypertension and Other Potential Indications

... advance its pipeline beyond traditional alpha-2 receptor agonists to compounds that would more selectively ... functions. Malfunctions in the alpha-2 receptor pathway have been implicated in a wide range of ... was selected as a lead compound because of its receptor subtype profile and because it had undergone ...

New strategies against bird flu

... IMBA-scientists identified ACE2 as the essential receptor for SARS virus infections and showed that ACE2 ... to show that a molecule called TLR4 (Toll-like receptor 4) is responsible for initiating the critical ... products are intrepreted as danger-signals by the receptor TLR4. Subsequently, the bodys innate immune ...

Astellas Launches Lexiscan(TM) (Regadenoson) Injection for Use as a Pharmacologic Stress Agent in Radionuclide Myocardial Perfusion Imaging (MPI)

... -First A2A Adenosine receptor Agonist Approved for Use in Identifying ... (regadenoson) injection, an A2A adenosine receptor agonist, for use as a pharmacologic stress agent ... (Nasdaq: CVTX ), is the first A2A adenosine receptor agonist shown to be safe and effective as ...

Commercial Launch of Lexiscan(TM) (Regadenoson) Injection Triggers $10 Million Milestone Payment from TPG-Axon Capital to CV Therapeutics

... injection, an A2A adenosine receptor agonist, for use as a pharmacologic stress agent ... injection Lexiscan(TM) is an A2A adenosine receptor agonist approved for use as a pharmacologic ... a functioning artificial pacemaker. Adenosine receptor agonists, including Lexiscan(TM), induce arterial ...

Memory Pharmaceuticals Reports First Quarter 2008 Financial Results

... path forward for our lead nicotinic alpha-7 receptor agonist, strengthens our financial profile and ... Pharmaceuticals' lead nicotinic alpha-7 receptor agonist, for further development and ... two partnered programs, its nicotinic alpha-7 receptor agonist collaboration with Roche and the ...

Human Genome Sciences Announces First Quarter 2008 Financial Results and Key Developments

... treatment phase - - Rights to TRAIL receptor antibodies reacquired - - GlaxoSmithKline ... In April, we reacquired rights to our TRAIL receptor antibodies and announced plans to begin our third ... In April, HGS reacquired rights to its TRAIL receptor antibodies HGS-ETR1 (mapatumumab) and HGS-ETR2 ...

Human Genome Sciences Advances Oncology Portfolio

... - HGS reacquires GSK rights to TRAIL receptor antibodies in return for ... that it has reacquired rights to the TRAIL receptor antibodies HGS-ETR1 (mapatumumab) and ... is commercialized. HGS is developing its TRAIL receptor antibodies for the treatment of a broad range of ...